Based on the heterogeneity tests, neurologic complications in the IDH-mutant astrocytoma (τ2 = 0.24, I2 = 47.39%) and the non-neurologic complications in the IDH-wildtype GBM group (τ2 = 0.06, I2 = 41.10%) demonstrated moderate heterogeneity. This evidence concerns the gene IDH1 and glioblastoma.